Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data

References

• Rey-Cárdenas M, Guerrero-Ramos F, Gómez de Liaño Lista A, et al. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: what to expect in the near future. Cancer Treat Rev. 2021;93:102142. doi: 10.1016/j.ctrv.2020.102142.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Bladder fact sheet [cited 2022 Nov 08]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/30-bladder-fact-sheet.pdf
   Google Scholar
• Witjes JA, Bruins HM, Carrión A, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer; 2022 [cited 2022 Nov 07]. Available from: https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
   Google Scholar
• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241. doi: 10.1016/j.eururo.2012.07.033.
   PubMed Web of Science ®Google Scholar
• Smith AB, Deal AM, Woods ME, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int. 2014;114(5):719–726. doi: 10.1111/bju.12601.
   PubMed Web of Science ®Google Scholar
• Fisher MD, Shenolikar R, Miller PJ, et al. Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015. Clin Genitourin Cancer. 2018;16(6):e1171–e1179. doi: 10.1016/j.clgc.2018.07.025.
   PubMed Web of Science ®Google Scholar
• Aly A, Johnson C, Yang S, et al. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. J Med Econ. 2019;22(7):662–670. doi: 10.1080/13696998.2019.1591424.
   PubMed Web of Science ®Google Scholar
• Stecca C, Abdeljalil O, Sridhar SS. Metastatic urothelial cancer: a rapidly changing treatment landscape. Ther Adv Med Oncol. 2021;13:17588359211047352. doi: 10.1177/17588359211047352.
   Web of Science ®Google Scholar
• Robert Koch-Institut. Cancer in Germany 2017/2018; 2021 [cited 2022 Nov 05]. Available from: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_inhalt.html
   Google Scholar
• Niegisch G, Gerullis H, Lin SW, et al. A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J Cancer. 2018;9(8):1337–1348. doi: 10.7150/jca.23162.
   PubMed Web of Science ®Google Scholar
• Jodon G, Fischer SM, Kessler ER. Treatment of urothelial cancer in elderly patients: focus on immune checkpoint inhibitors. Drugs Aging. 2018;35(5):409–421. doi: 10.1007/s40266-018-0540-8.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012;39(5):598–607. doi: 10.1053/j.seminoncol.2012.08.007.
   PubMed Web of Science ®Google Scholar
• Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;33(3):244–258. doi: 10.1016/j.annonc.2021.11.012.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi: 10.1056/NEJMoa1613683.
   PubMed Web of Science ®Google Scholar
• Gemeinsamen Bundesausschusses (G-BA). Arzneimittel-Richtlinie/Anlage XII: Atezolizumab (Urothelkarzinom). Berlin: G-BA; 2018 [cited 2023 Jun 14]. Available from: https://www.g-ba.de/downloads/39-261-3256/2018-03-16_AM-RL-XII_Atezolizumab_D-314_BAnz.pdf
   Google Scholar
• Gemeinsamen Bundesausschusses (G-BA). Arzneimittel-Richtlinie/Anlage XII: Pembrolizumab (neues Anwendungsgebiet: Urothelkarzinom). Berlin: G-BA; 2018 [cited 2023 Jun 14]. Available from: https://www.g-ba.de/downloads/39-261-3257/2018-03-16_AM-RL-XII_Pembrolizumab_D-311_BAnz.pdf
   Google Scholar
• Gemeinsamen Bundesausschusses (G-BA). Arzneimittel-Richtlinie/Anlage XII: Nivolumab (neues Anwendungsgebiet: Urothelkarzinom). Berlin: G-BA; 2017 [cited 2023 Jun 14]. Available from: https://www.g-ba.de/beschluesse/3170/
   Google Scholar
• Gemeinsamen Bundesausschusses (G-BA). Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V: Avelumab. Berlin: G-BA; 2021 [cited 2023 Jun 14]. Available from: https://www.g-ba.de/downloads/39-261-4981/2021-08-19_AM-RL-XII_Avelumab_D-646_BAnz.pdf
   Google Scholar
• Niegisch G, Grimm M-O, Hardtstock F, et al. Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: a retrospective analysis of real-world data in Germany. J Clin Oncol. 2023;41(6_suppl):464–464. doi: 10.1200/JCO.2023.41.6_suppl.464.
   Google Scholar
• Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39. doi: 10.1208/s12248-021-00574-0.
   PubMed Web of Science ®Google Scholar
• Powles T, Bellmunt J, Comperat E, et al. Bladder Cancer: ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024. doi: 10.1016/j.annonc.2024.03.001.
   PubMedGoogle Scholar
• Leal J, Luengo-Fernandez R, Sullivan R, et al. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69(3):438–447. doi: 10.1016/j.eururo.2015.10.024.
   PubMed Web of Science ®Google Scholar
• Destatis (Statistisches Bundesamt). Bevölkerungsstand: Amtliche Einwohnerzahl Deutschlands; 2022. Wiesbaden: Destatis; 2023 [cited 2023 Jun 14]. Available from: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Bevoelkerungsstand/_inhalt.html
   Google Scholar
• Schwarzkopf L. Evidence generation in health services research - illustrative examples and conceptual thoughts on claims data-based applications: Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH). Munich (Germany): Ludwig-Maximilians-Universität München 2018.
   Google Scholar
• De Wit M, Bauernhofer T, Bokemeyer C, et al. Blasenkarzinom (Urothelkarzinom). Berlin (Germany): DGHO (Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie); 2019.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27. doi: 10.1097/00005650-199801000-00004.
   PubMed Web of Science ®Google Scholar
• Destatis. (Statistisches Bundesamt.). Per capita costs of illness for men and women continue to converge 2022 [cited 2024 Mar 20]. Available from: https://www.destatis.de/EN/Press/2022/07/PE22_316_236.html
   Google Scholar
• Kearney M, Esposito D, Russo L, et al. Locally advanced or metastatic urothelial carcinoma in the United States: economic burden and healthcare utilization. Value Health. 2018;21:S45. doi: 10.1016/j.jval.2018.04.261.
   Web of Science ®Google Scholar
• Morgans AK, Hepp Z, Shah SN, et al. Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: a Medicare claims database analysis. Urol Oncol. 2021;39(10):733 e1–733–e10. doi: 10.1016/j.urolonc.2021.05.001.
   Web of Science ®Google Scholar
• Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295–300. doi: 10.1007/s00345-009-0395-z.
   PubMed Web of Science ®Google Scholar
• Liu D, Mehta D, Kaur S, et al. Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. J Hematol Oncol. 2018;11(1):138. doi: 10.1186/s13045-018-0682-5.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi: 10.1038/s41571-019-0218-0.
   PubMed Web of Science ®Google Scholar
• Bundesministerium für Gesundheit. § 39 SGB V Krankenhausbehandlung; 2023 [cited 2023 Jun 14]. Available from: https://www.sozialgesetzbuch-sgb.de/sgbv/39.html
   Google Scholar
• Tariman JD, Doorenbos A, Schepp KG, et al. Patient, physician and contextual factors are influential in the treatment decision making of older adults newly diagnosed with symptomatic myeloma. Cancer Treat Commun. 2014;2(2-3):34–47. doi: 10.1016/j.ctrc.2014.08.003.
   PubMedGoogle Scholar
• Rosen RD, Sapra A. TNM classification. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
   Google Scholar
• Lang LM, Behr C, Ludwig M, et al. Routine practice data of three cancer entities: comparison among cancer registry and health insurance data. Z Evid Fortbild Qual Gesundhwes. 2023;177:65–72.
   PubMed Web of Science ®Google Scholar
• Institute for Quality and Efficiency in Health Care (IQWiG). Pembrolizumab (Urothelkarzinom Erstlinientherapie) - Nutzenbewertung gemäß § 35a SGB V; 2017 [cited 2022 Nov 04]. Available from: https://www.iqwig.de/download/a21-34_pembrolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
   Google Scholar
• Institute for Quality and Efficiency in Health Care (IQWiG). Atezolizumab (Urothelkarzinom Erstlinientherapie) – Nutzenbewertung gemäß § 35a SGB V; 2017 [cited 2022 Nov 04]. Available from: https://www.iqwig.de/download/a17-51_atezolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
   Google Scholar
• Institute for Quality and Efficiency in Health Care (IQWiG). Nivolumab (Urothelkarzinom) – Nutzenbewertung gemäß § 35a SGB V; 2017 [cited 2022 Nov 05]. Available from: https://www.iqwig.de/download/a17-29_nivolumab_nutzenbewertung-35a-sgb-v_v1-0.pdf?rev=117386
   Google Scholar
• Bundesministerium für Gesundheit. Versicherte in der gesetzlichen Krankenversicherung; 2022 [cited 2023 Apr 11]. Available from: https://www.bundesgesundheitsministerium.de/gesetzlich-versicherte.html#:∼:text=Kinder%2C%20Ehegattinnen%20und%20Ehegatten%20sowie,eine%20bestimmte%20Einkommensgrenze%20nicht%20regelm%C3%A4%C3%9Fig
   Google Scholar